Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8983)
All Articles published online
|
Jul 26, 2010 (publication date) through Jan 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Biological Chemistry
ISSN
1949-8454
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem 2010; 1(7): 209-220 [PMID: 21537476 DOI: 10.4331/wjbc.v1.i7.209] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8454/full/v1/i7/209.htm |
| Number | Citing Articles |
| 1 |
Hiroaki Itamochi, Misaki Kato, Mayumi Nishimura, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Seiya Sato, Michiko Nonaka, Akiko Kudoh, Naoki Terakawa, Junzo Kigawa, Tasuku Harada. Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. Human Cell 2012; 25(4): 111 doi: 10.1007/s13577-012-0048-1
|
| 2 |
Rexxi D. Prasasya, Kang Z. Vang, Pamela K. Kreeger. A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. Biotechnology and Bioengineering 2012; 109(1): 213 doi: 10.1002/bit.23297
|
| 3 |
Shinya Sato, Hiroaki Itamochi. Bevacizumab and ovarian cancer. Current Opinion in Obstetrics & Gynecology 2012; 24(1): 8 doi: 10.1097/GCO.0b013e32834daeed
|
| 4 |
Renu A. Kowluru, Manish Mishra. Contribution of epigenetics in diabetic retinopathy. Science China Life Sciences 2015; 58(6): 556 doi: 10.1007/s11427-015-4853-0
|
| 5 |
Merete Thune Wiiger, Hemaseh Bideli, Øystein Fodstad, Kjersti Flatmark, Yvonne Andersson. The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells. Journal of Ovarian Research 2014; 7(1) doi: 10.1186/1757-2215-7-23
|
| 6 |
Federica Tomao, Anselmo Papa, Luigi Rossi, Martina Strudel, Patrizia Vici, Giuseppe Lo Russo, Silverio Tomao. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Journal of Experimental & Clinical Cancer Research 2013; 32(1) doi: 10.1186/1756-9966-32-48
|
| 7 |
Heejin Lee, Jun Woo Kim, Dong-Seok Lee, Sang-Hyun Min. Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness. International Journal of Molecular Sciences 2020; 21(19): 7379 doi: 10.3390/ijms21197379
|
| 8 |
Kimberly K. Leslie, Kristina W. Thiel, Michael J. Goodheart, Koen De Geest, Yichen Jia, Shujie Yang. Endometrial Cancer. Obstetrics and Gynecology Clinics of North America 2012; 39(2): 255 doi: 10.1016/j.ogc.2012.04.001
|
| 9 |
Donavon Hiss. Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. Journal of Oncology 2012; 2012: 1 doi: 10.1155/2012/737981
|
| 10 |
Wei Wei, Yan Li, Shuqing Lv, Cancan Zhang, Yongjie Tian. PARP-1 may be involved in angiogenesis in epithelial ovarian cancer. Oncology Letters 2016; 12(6): 4561 doi: 10.3892/ol.2016.5226
|
| 11 |
Xiaolin Yu, Zhaoxia Liu, Rui Hou, Yijun Nie, Rensheng Chen. Nerve growth factor and its receptors on onset and diagnosis of ovarian cancer. Oncology Letters 2017; 14(3): 2864 doi: 10.3892/ol.2017.6527
|
| 12 |
Dong Hoon Suh, Min A. Kim, Haeryoung Kim, Mi-Kyung Kim, Hee Seung Kim, Hyun Hoon Chung, Yong-Beom Kim, Yong Sang Song. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clinical and Experimental Medicine 2014; 14(3): 345 doi: 10.1007/s10238-013-0250-9
|
| 13 |
Hiroaki Itamochi, Junzo Kigawa. Clinical trials and future potential of targeted therapy for ovarian cancer. International Journal of Clinical Oncology 2012; 17(5): 430 doi: 10.1007/s10147-012-0459-8
|
| 14 |
IKUE NAKAYAMA, MASAHIKO SHIBAZAKI, AKIKO YASHIMA-ABO, FUMIHARU MIURA, TORU SUGIYAMA, TOMOYUKI MASUDA, CHIHAYA MAESAWA. Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells. International Journal of Oncology 2013; 43(1): 63 doi: 10.3892/ijo.2013.1935
|
| 15 |
Ayako Kim, Yutaka Ueda, Tetsuji Naka, Takayuki Enomoto. Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 2012; 31(1) doi: 10.1186/1756-9966-31-14
|
| 16 |
Hina Mir, Gurpreet Kaur, Neeraj Kapur, Sejong Bae, James W. Lillard, Shailesh Singh. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-38766-6
|
| 17 |
Junzo Kigawa. Molecular-targeted therapies for ovarian cancer. International Journal of Clinical Oncology 2012; 17(5): 423 doi: 10.1007/s10147-012-0456-y
|
| 18 |
Yuanqi He, Liqun Wei, Shihong Zhang, Haining Liu, Fang Fang, Yue Li. <p>LncRNA PLAC2 Positively Regulates CDK2 to Promote Ovarian Carcinoma Cell Proliferation</p>. Cancer Management and Research 2020; : 5713 doi: 10.2147/CMAR.S242781
|
| 19 |
ZHONGYUAN TANG, NING ZHANG, WEN DI, WEIPING LI. Inhibition of microtubule-associated protein 1 light chain 3B via small-interfering RNA or 3-methyladenine impairs hypoxia-induced HO8910PM and HO8910 epithelial ovarian cancer cell migration and invasion and is associated with RhoA and alterations of the actin cytoskeleton. Oncology Reports 2015; 33(3): 1411 doi: 10.3892/or.2015.3742
|
| 20 |
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget 2017; 8(23): 37061 doi: 10.18632/oncotarget.15715
|
| 21 |
Seiya Sato, Hiroaki Itamochi, Nao Oumi, Youhei Chiba, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Chikumi, Michiko Nonaka, Akiko Kudoh, Hiroaki Komatsu, Tasuku Harada, Toru Sugiyama. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression. Human Cell 2016; 29(4): 181 doi: 10.1007/s13577-016-0138-6
|
| 22 |
Hiroaki Itamochi, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Kazunori Uegaki, Jun Naniwa, Seiya Sato, Michiko Nonaka, Naoki Terakawa, Junzo Kigawa, Tasuku Harada. Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-Jun. Clinical Cancer Research 2011; 17(14): 4742 doi: 10.1158/1078-0432.CCR-11-0190
|
| 23 |
|
| 24 |
Juelan Wang, Wenqian Xu, Yangke He, Qi Xia, Siwei Liu. LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflammation Research 2018; 67(11-12): 927 doi: 10.1007/s00011-018-1186-z
|
| 25 |
JIE ZHANG, WENJING WANG, LIN QIAN, QIUWAN ZHANG, DONGMEI LAI, CONG QI. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition. Oncology Reports 2015; 34(5): 2375 doi: 10.3892/or.2015.4213
|
| 26 |
Racheal L. James, Taryn Sisserson, Zhuangyu Cai, Megan E. Dumas, Landon J. Inge, James Ranger-Moore, Albert Mason, Callum M. Sloss, Katherine McArthur. Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine. Archives of Pathology & Laboratory Medicine 2024; 148(11): 1226 doi: 10.5858/arpa.2023-0149-OA
|
| 27 |
Carlotta Defferrari, Sara Campora, Mauro D'Amico, Arnoldo Piccardo, Ennio Biscaldi, Daniela Rosselli, Ambra Pasa, Matteo Puntoni, Alberto Gozza, Alessandra Gennari, Silvia Zanardi, Rita Lionetto, Michela Bandelloni, Andrea DeCensi. A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. Journal of Ovarian Research 2012; 5(1) doi: 10.1186/1757-2215-5-17
|
| 28 |
HIROSHI SHIGETOMI, YUMI HIGASHIURA, HIROTAKA KAJIHARA, HIROSHI KOBAYASHI. Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review). Oncology Reports 2012; 28(2): 395 doi: 10.3892/or.2012.1833
|
| 29 |
Kristsanamon Rittiluechai, Yongli Ji, Karen Lounsbury, Alan Howe, Claire Verschraegen. International Manual of Oncology Practice. 2015; : 393 doi: 10.1007/978-3-319-21683-6_18
|
| 30 |
Taner Korkmaz, Selcuk Seber, Gul Basaran. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. Critical Reviews in Oncology/Hematology 2016; 98: 180 doi: 10.1016/j.critrevonc.2015.10.006
|
| 31 |
FUQIANG YIN, XIA LIU, DANRONG LI, QI WANG, WEI ZHANG, LI LI. Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. International Journal of Oncology 2013; 42(4): 1305 doi: 10.3892/ijo.2013.1819
|
| 32 |
XIUJIE SHENG, JIANQI LI, LEI YANG, ZHIYI CHEN, QIN ZHAO, LINYU TAN, YANQING ZHOU, JUAN LI. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncology Reports 2014; 32(1): 277 doi: 10.3892/or.2014.3208
|
| 33 |
Renu A. Kowluru, Anjan Kowluru, Manish Mishra, Binit Kumar. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Progress in Retinal and Eye Research 2015; 48: 40 doi: 10.1016/j.preteyeres.2015.05.001
|
| 34 |
Hiroaki Itamochi, Misaki Kato, Mayumi Nishimura, Nao Oumi, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Seiya Sato, Michiko Nonaka, Akiko Kudoh, Naoki Terakawa, Junzo Kigawa, Tasuku Harada. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Human Cell 2013; 26(3): 121 doi: 10.1007/s13577-013-0062-y
|
| 35 |
Mahima Mahima, Tarique Mahmood, Akash Ved, Mohammed Haris Siddiqui, Farogh Ahsan, Arshiya Shamim, Vaseem Ahamad Ansari, Afroz Ahmad, Monu Kumar Kashyap. An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical
Manifestation. Drug Research 2022; 72(08): 424 doi: 10.1055/a-1867-4654
|